Future research could first use N-of-1 trials to identify response prototypes (e.g., microbiome-driven, insulin-sensitive, and lifestyle-dependent) and then validate subgroup-specific interventions through targeted randomized controlled trials, thereby balancing precision and scalability, and offering new insights for individualized interventions in diabetes management. This evidence concerns the gene INS and diabetes mellitus.